Skip to main content
. Author manuscript; available in PMC: 2013 Jan 15.
Published in final edited form as: J Immunol. 2011 Dec 19;188(2):641–648. doi: 10.4049/jimmunol.1101925

Figure 5. Decreased complement activation, IgM levels and IgM deposition in IL-4-deficient mice.

Figure 5

A) Graph showing the levels of complement cleavage products (C3b/iC3b/C3c) in the plasma of WT and IL4−/− mice after PHx. Values represent percentages of values for cobra venom factor (CVF)-activated serum, which was considered to cause 100% complement activation. Data are presented as means ± s.e.m. (n = 4–6 [WT] and 4–5 [IL-4−/−] mice per time point). p < 0.0001, two-way ANOVA. B) Graph of IgM levels in the plasma of WT and IL-4−/− mice before (0 h) and 2–3 h after PHx. Data are presented as means + s.e.m. (n = 11–16 [WT] and 5–9 [IL-4−/−] mice per time point). *, p = 0.0022, t-test; **, p = 0.0326, t-test; *** p = 0.0316, t-test. C) Immunofluorescent staining for IgM deposition in liver sections from WT mice before (0 h) or 2 h after PHx. Bright green staining indicates the presence of deposited IgM. Immunofluorescence at 2 h is representative of staining seen at 2 and 3 h after PHx (n = 3–4 mice per time point). D) Same staining as in (C), but for IL-4−/− mice (n = 3–4 mice per time point). Scale bar = 100 μm. CV, central vein.